A recent, pivotal Phase III global study—randomizing 250 patients
over 51 global sites to study a lipid altering therapy— was completed
in record time to the Sponsor’s approval. The key to the project’s
successful completion was deep expertise in the therapeutic area,
a well-developed site relationship in emerging markets, and the
implementation of a strong communication plan utilizing a best-in-class
technology platform to achieve accelerated patient recruitment.